Background The majority of RA treatments target inflammation or the adaptive immune response. Partial- or non-response is common and only a minority have sustained remission. There is a knowledge gap in understanding the mechanisms that could reinstate synovial homeostasis in RA. Tissue macrophages may have a role in this process; they are present in healthy synovium and aid resolution of the inflammation in experimental models of RA. However, little is known about the regulatory properties of human synovial tissue macrophages.
Objectives Our hypothesis is that healthy and RA synovium in remission contain macrophages with anti-inflammatory/repair properties and identifying the effector pathways that drive their function could facilitate therapeutic restoration of synovial homeostasis in RA.
Methods We developed a flow cytometry sorting strategy for harvesting tissue-resident macrophages obtained from digested synovial biopsies of RA patients (n=21, including in remission n=5; and active RA n=16). Cells were labelled with cell lineage-specific antibodies; then macrophages were gated based on their expression of CD64posCD11bposMHCIIposLineageneg. The potential homeostatic/repair macrophage was preliminary identified by the presence of CD206 marker. CD206pos and CD206neg macrophages were sorted using a FACS Aria III and RNAseq performed to characterise their functional signature. In some experiment, macrophages were seeded on collagen-coated plates and production of TNFa evaluated.
Results All synovial tissue macrophages from RA in remission were CD206pos whereas a substantial number of synovial macrophages from active RA tissue were CD206neg. Gene expression analyses and functional assays suggest that these populations represent distinct phenotypes in the activation spectrum. CD206neg macrophages have high expression of microRNA-155, which drives production of inflammatory mediators e.g. TNFa. In contrast, CD206pos macrophages showed regulatory properties characterised by increased expression of soluble (e.g. IL10, TGFB), surface (e.g. IL4/14R, TGFBR1/2) and cellular (e.g. SHIP1, TAM, SMAD2, STAT6) inhibitors of inflammatory activation, and increased expression of repair markers (e.g. ARG2 and CCL18).
Conclusions We propose therefore that anti-inflammatory/repair macrophages may be present in human synovial tissues in remission representing a hitherto unnoticed regulatory tissue mechanism.
Smolen JS, Aletaha D, McInnes IB. Rheumatoid Arthritis. Lancet Volume 388, Issue 10055, 22–28 October 2016, Pages 2023–2038.
Misharin AV et al. Non-classical Ly6C(-) monocytes drive the development of inflammatory arthritis in mice. Cell Rep. 2014;9:591.
Kurowska-Stolarska M, Alivernini S et al. MicroRNA-155 as a pro-inflammatory regulator in clinical and experimental arthritis. PNAS 2011;108:11193.
Elmesmari A, McInnes IB, Kurowska-Stolarska M. MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis. Rheumatology (Oxford). 2016 Nov;55(11):2056–2065. Epub 2016 Jul. 13.
Disclosure of Interest None declared